Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-01

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the efficacy of Two different regimens of proton pump inhibitors High against Low in the management of acute peptic ulcer bleeding

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers

NCT03163680

Gastroduodenal Ulcer Marginal Ulcer Peptic Ulcer Hemorrhage

COMPLETED

High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding

NCT00374101

Peptic Ulcers Upper Gastrointestinal Bleeding

COMPLETED PHASE3

Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding

NCT03814421

Peptic Ulcer Hemorrhage Peptic Ulcer, Acute With Hemorrhage Peptic Ulcer +1 more

UNKNOWN NA

Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed

NCT02235311

Upper Gastrointestinal Bleed

TERMINATED NA

Oral Omeprazole in Bleeding Peptic Ulcer

NCT04170270

Bleeding Peptic Ulcer

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluate the efficacy of Two different regimens of proton pump inhibitors in the management of acute peptic ulcer bleeding First: loading dose 80 mg then 8mg/h iv continuous infusion for 3 days Second Loading dose 80 mg the 40 mg every 12 h for 3 days

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroduodenal Ulcer Marginal Ulcer Peptic Ulcer Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Omeprazole High dose

Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days

Group Type ACTIVE_COMPARATOR

Omeprazole High dose

Intervention Type DRUG

High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days

Omeprazole Low Dose

Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days

Group Type EXPERIMENTAL

Omeprazole Low dose

Intervention Type DRUG

low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omeprazole High dose

High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days

Intervention Type DRUG

Omeprazole Low dose

low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* High risk ulcers defined according to the Forrest classification With respect to high-risk stigmata,
* active bleeding was defined as a continuous blood spurting (Forrest IA)
* oozing (Forrest IB) from the ulcer base.
* A non-bleeding visible vessel at endoscopy was defined as a discrete protuberance at the ulcer base(Forrest IIA).
* An adherent clot was one that was resistant to forceful irrigation or suction (Forrest IIB).